Senlizumab

(BAN)
Synonyms: Bay-10-3356; Bay-w-3356; CDP-571.
Cyrillic synonym: Сенлизумаб.

Chemical information

CAS — 336128-48-4.

Profile

Senlizumab is a humanised monoclonal antibody to tumour necrosis factor. It has been investigated in the treatment of Crohn’s disease, ulcerative colitis, and rheumatoid arthritis.
1. Rankin EC, et al. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 1995; 34: 334–42
2. Evans RC, et al. Treatment of ulcerative colitis with an engineered human anti-TNF alpha antibody CDP571. Aliment Pharmacol Ther 1997; 11: 1031–5
3. Stack WA, et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn’s disease. Lancet 1997; 349: 521–4
4. Anonymous. CDP 571: anti-TNF monoclonal antibody, BAY 103356, BAY W 3356, Humicade. Drugs R D 2003; 4: 174–8
5. Sandborn WJ, et al. CDP571, a humanised monoclonal antibody to tumour necrosis factor α, for moderate to severe Crohn’s disease: a randomised, double blind, placebo controlled trial. Gut 2004; 53: 1485–93
6. Mamula P, et al. CDP571, a humanized anti-tumor necrosis factor-alpha monoclonal antibody in pediatric Crohn’s disease. Inflamm Bowel Dis 2004; 10: 723–30
7. Feagan BG, et al. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn’s disease. Aliment Pharmacol Ther 2005; 21: 373–84
8. Feagan BG, et al. CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2006; 23: 617–28.
Published May 08, 2019.